A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer

Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00534807

Enrollment

Registered

2007-09-26

Start date

2007-09-30

Completion date

2008-11-30

Last updated

2015-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

The purpose of this study is to test how vinflunine interacts with rifampin in the human body

Interventions

DRUGVinflunine

DRUGRifampin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Cancer unresponsive to previous treatment * Consent for genetic samples

Exclusion criteria

* Cancer of the blood * Spread of cancer to the brain * Moderate or severe nerve damage * Low white blood cell counts and platelet counts * Inadequate liver or kidney function * Prior treatment with vinflunine * Use of certain medications that might interfere with the metabolism of vinflunine

Design outcomes

Primary

Measure	Time frame
The Primary Outcome Measure of the effect of rifampin on the pharmacokinetics (PK) of intravenous (IV) vinflunine will be determined from the PK measurements	taken during Cycle 2 of study treatment, at approximately 4 weeks after the start of study treatment

Secondary

Measure	Time frame
The Secondary Outcome Measures of the safety and tolerability of vinflunine when administered alone and with rifampin	determined after 2 complete 21-day Cycles of study treatment, at approximately 6 weeks after the start of study treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026